This secondary analysis of data from the the FAP Erlotinib-Sulindac Trial (FAPEST) trial examines the effect of sulindac and erlotinib on colorectal adenoma formation and regression in patients with familial adenomatous polyposis.
http://ift.tt/2nU5KNR
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Publication date: Available online 22 March 2017 Source: Medical Journal Armed Forces India Author(s): S.C. Shaw, M.S. Vinod, Amit Devgan ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου